Ranibizumab biosimilar (CJ HealthCare)

雷珠单抗生物类似药 (CJ HealthCare)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRanibizumab biosimilar (CJ HealthCare)

Drug Alias Name雷珠单抗生物仿制药 (CJ HealthCare)CJ-40012

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHK inno.N Corporation

China Registration ClassN/A

Develop Information

Active CompaniesHK inno.N Corporation

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeS01LA04